retatrutide bahrain ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Bahrain: Repression Marks Uprising Anniversary
Description
TRANSCEND-T2D-1 randomized 537 adults with type 2 diabetes (baseline A1c 7.0 to 9.5 percent, inadequately controlled on diet and exercise alone) to retatrutide 4 mg, 9 mg, 12 mg, or placebo for 40 weeks
Esto te ayuda a mantenerte en forma, tanto en casa como fuera de ella.
Regulatory authorization for new drug for first indication, defined as Novel Drug Approval by FDA, and Marketing Authorization for New Active Substance by EMA.
Anesth Analg 118(5):938944
This is exactly why the REDEFINE 4 trial exists
For those taking insulin or sulfonylureas, this may increase hypoglycaemia risk, requiring medication review
